Home Companies What’s taking the Akari Therapeutics Plc (AKTX) stock to new heights?

What’s taking the Akari Therapeutics Plc (AKTX) stock to new heights?

Akari Therapeutics, Plc (Nasdaq: AKTX) a clinical-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases, confirmed that the U.S. Food and Drug Administration has granted Fast Track designation to nomacopan to treat patients affected with BP.  AKTX stock surged adjacent to the news.

At last check-in current trading, shares of Akari Therapeutics Plc (AKTX) were up 3.85% at $2.43. The price range of the company’s shares was between $2.31 and $2.38. It traded 9.19 million shares, which was above its daily average of 0.39 million shares over 100 days. The company had an earnings per share ratio of -0.63.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


About Akari Therapeutics

Nomacopan has seen fast track to facilitate the development and treatment of serious conditions such as BP, and provide the patient with the drug as early as possible. Nomacopan receiving Fast Track could provide repeated meetings with FDA to review the drug’s development plan which may be inclusive of the design of the proposed clinical trials, and adequate data required for further approval.

A positive result to treat BP could potentially open up various other dermatological illnesses for treatment with nomacopan, including hidradenitis suppurativa, epidermolysis bullosa acquisita, and mucous membrane pemphigoid. Akari’s leading drug, Nomacopan is a C5 complement inhibitor that particularly binds to and inhibits leukotriene B4 (LTB4) activity.

BP is a severe orphan autoimmune disease that causes blistering and has no approved methods of treatment in the US and Europe.  The disease especially targets the elderly and firsthand treatment includes steroids and immunosuppressants for six months which may cause several side effects and a threefold increase in mortality in the BP-treated demographic.

BP is expected to have almost 120,000 patients in U.S. and EU5 with 75% of the patient population consisting of moderate and severe cases. In BP patients no adequate evidence is present that terminal complement activation has a major role in driving the illness. Furthermore, FDA approval of the Investigational New Drug Application (IND) allows clinical facilities to open in U.S. and Europe in mid-2021.

Conclusion

FDA approval of Akari Therapeutics manufactured drug nomacopan has peaked investor interest with AKTX surging at last check. Fast track of the drug may open several avenues for treatment of several diseases with most patients reporting moderate to severe cases.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

Intec Pharma Inc. (NTEC) stock declines during current market after a massive upraise. What’s happening?

Intec Pharma Inc. (NASDAQ: NTEC) stock drops by 7.88% during the current market trading session. Intec Pharma is a clinical-stage biopharmaceutical firm specializing in...

Related News

Lumentum Holdings Inc. (LITE) Stock Drops Despite Promising Fiscal Q3 2021 Financial Reports

Lumentum Holdings Inc. (LITE) stock prices were down by a significant 16.42% shortly after market trading commenced, bringing the price per share down to...

Lucira Health Inc. (NASDAQ:LHDX) stock rallied today in the current trading session; here’s why

In the current trading session at last check, Lucira Health Inc. (LHDX) shares had surged by 15.32% to the price of $5.87. LHDX's stock...

Comstock Mining Inc. (NASDAQ:LODE) stock plunged in the current trading session; here’s why

In the current trading session at the last check, Comstock Mining Inc. (LODE) stock had plunged -3.25% to trade at $3.21. LODE stock previously...

Greenpro Capital Corp. (GRNQ) Stock Price Is Rising Immensely, Here is What You Need to Know

Greenpro Capital Corp. (NASDAQ: GRNQ) a leading company primarily focused on the provision of cloud system resolution, financial consulting services, and corporate accounting services,...

Tilray Inc. (NASDAQ: TLRY) stock rises during current market trading. What is driving it high?

Tilray Inc. (NASDAQ: TLRY) stock gains by 17.17% in the current market trading. Tilray is a world leader in cannabis and cannabinoid research, cultivation,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam